|Awarded On||November 16, 2016|
|Title||Genetic Epidemiology and Molecular Basis of Cancer Predisposition in Pediatric Rhabdomyosarcoma|
|Award Mechanism||Individual Investigator Research Awards for Prevention and Early Detection|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Philip Lupo|
Compared to other pediatric cancers, the outlook for children with rhabdomyosarcoma (RMS) remains poor. In particular, for those with high-risk disease, fewer than 43% of patients survive for more than 5 years. Currently, there are no genetic testing and counseling strategies for children with RMS; there are no clinical surveillance or prevention protocols; and there are few therapeutic targets for this highly fatal tumor. One of the strongest risk factors for RMS is having a genetic cancer predisposition syndrome. While it is believed that about 7% of RMS patients have changes (or mutations) in the genes responsible for these syndromes, there have been: 1) no population-based assessments t...